Peritoneal dialysis solution comprising electrolytes in physiological amounts and at least one osmotically active substance which additionally comprises as antimicrobial substance sorbic acid in an amount of 0.001 to 1% by weight and a pH value of 4 to 7.
The present invention contemplates the addition of 0.5% to 4% taurolidine into solutions used peritoneal dialysis. The taurolidine is intended to prevent or reduce the incidence of infection within the abdomen and/or in the vicinity of an implanted dialysis port. The invention also includes methods using solutions of taurolidine in the flushing and locking of catheters and fluid lines used in peritoneal dialysis.
A method of inhibiting adherence of bacteria, fungus and other similar microorganisms to the surface of biomaterials is disclosed wherein biomaterials such as catheters and prosthetic devices are pretreated with a coating of a simple carbohydrate such as a mono- or di-saccharide. Intravascular catheters treated as such are shown to have significant reduction of adherence by S. epidermidis, S. aureus, Candidas and other organisms associated with nosocomial infection.
The invention relates to a substitution infusion fluid for hemofiltration of a specific composition. The use of said substitution infusion fluid significantly reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration. The invention also relates to process for pure hemofiltration of blood wherein said substitution infusion fluid is used. The invention also relates to a matching citrate anticoagulation fluid of a specific composition. The invention also relates to a process for pure hemofiltration of blood wherein said substitution infusion fluid is used in combination with said citrate anticoagulation fluid. The use of said substitution infusion fluid in combination with said citrate anticoagulation fluid significantly further reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration.
A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
